whole-cell pertussis vaccine

Vaccineexperimental

Pertussis vaccine is a vaccine that protects against whooping cough (pertussis). There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective. The effectiveness of the vaccines appears to decrease by between 2 and 10% per year after vaccination, with a more rapid decrease with the acellular vaccines. The vaccine is only available in combination with tetanus and diphtheria vaccines. Pertussis vaccine is estimated to have saved over 500,000 lives in 2002. — Wikipedia

Clinical trial activity

2 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
1

Earliest trial started Apr 1, 1991 (NCT00004799)

Timeline

1990s

  1. Jan 1, 1991

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • whole-cell pertussis vaccine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03606096Phase 4Sep 30, 2018Imperial College London, Leiden University, National Institute for Public Health and the Environment, RIVM, Holland, Radboud University, University of London, University of Oxford, University of Turku
NCT00004799Phase 3Apr 1, 1991National Institute of Allergy and Infectious Diseases (NIAID)
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Imperial College LondonAcademic/Hospital1012018
Leiden UniversityAcademic/Hospital1012018
National Institute for Public Health and the Environment, RIVM, HollandGovernment1012018
National Institute of Allergy and Infectious Diseases (NIAID)Government1111991
Radboud UniversityAcademic/Hospital1012018
University of LondonAcademic/Hospital1112018
University of OxfordAcademic/Hospital1012018
University of TurkuAcademic/Hospital1012018
8 organizations
Page 1 / 1